Crizotinib

Chemical formula: C₂₁H₂₂Cl₂FN₅O  Molecular mass: 450.337 g/mol  PubChem compound: 11626560

Therapeutic indications

Crizotinib is indicated for:

Non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK)-positive

Population group: only adults (18 years old or older)

Crizotinib as monotherapy is indicated for:

  • The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
  • The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

ROS1-positive advanced non-small cell lung cancer (NSCLC)

Population group: only adults (18 years old or older)

Crizotinib as monotherapy is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: XALKORI Hard capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈